Navidea Biopharmaceuticals has released preliminary results of the Phase IIb clinical trial evaluating its beta amyloid PET imaging agent NAV4694. Findings support the tracer's safety and efficacy in imaging patients with mild cognitive impairment. The tracer produced high-quality diagnostic images that were used to separate patients with MCI into amyloid-positive and amyloid-negative groups.

Full Story:
RTT News

Related Summaries